Skip to main content
Nanobiotix logo

Nanobiotix — Investor Relations & Filings

Ticker · NANO ISIN · FR0011341205 LEI · 969500667RSYIH8YL895 PA Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2016-01-07 Regulatory Filings
Country FR France
Listing PA NANO

About Nanobiotix

https://www.nanobiotix.com/

Nanobiotix is a late-stage clinical biotechnology company pioneering a physics-based approach to cancer treatment through the development of nanotherapeutics. Its lead product candidate, NBTXR3, is a potential first-in-class radioenhancer designed to be injected directly into a tumor. When activated by radiotherapy, NBTXR3 amplifies the radiation dose within the tumor, aiming to destroy cancer cells more effectively without increasing exposure to surrounding healthy tissues. This process is also intended to prime an immune response to target metastatic tumors. The company is developing NBTXR3 for broad application across various solid tumors, with an initial focus on head, neck, and lung cancers through a global licensing agreement with Janssen Pharmaceutica NV.

Recent filings

Filing Released Lang Actions
Rachat d'actions / Contrat de liquidité Information relative au contrat de liquidité
Regulatory Filings Classification · 99% confidence The document is titled "2015 : BILAN ANNUEL DU CONTRAT DE LIQUIDITE CONTRACTE AVEC LA SOCIETE DE BOURSE GILBERT DUPONT" and provides a year-end (December 31, 2015) summary of the liquidity contract holdings (shares and cash balance), comparing it to the previous semi-annual balance (June 30, 2015). This type of regular update concerning the maintenance of a liquidity contract (market making arrangement) is typically a regulatory disclosure related to share transactions or market stability, but it is not a standard financial report (10-K, IR) or a director's dealing report (DIRS). It specifically details the status of shares held under a specific agreement. Given the options, this is a specific regulatory disclosure that doesn't fit perfectly into the main financial reports or management changes. It is most closely related to share activity or general regulatory announcements. Since it details the status of shares held under a specific arrangement, and it is not a standard dividend notice (DIV) or a general share issue (SHA), it falls best under the general 'Regulatory Filings' (RNS) as a specific, non-standard disclosure, or potentially related to capital/financing updates (CAP) if the liquidity contract is viewed as a financing tool. However, given the context of market making/liquidity provision updates, RNS is the most appropriate fallback for specific, non-core regulatory disclosures not covered elsewhere. The document length is short (2587 chars), but it is a substantive report on the contract status, not just an announcement of another report.
2016-01-07 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 95% confidence The document is a press release dated January 5, 2016, announcing that Nanobiotix has started a new research program in Immuno Oncology using its lead product NBTXR3. It details ongoing clinical trials and the scientific rationale for the new program. This type of announcement, which communicates a significant business or research development via a press release format, is typically classified as an Earnings Release (ER) if it relates to periodic results, or more generally as a Regulatory Filing (RNS) if it's a general corporate update that doesn't fit a more specific category like M&A (TAR) or Capital Change (CAP). Since this is a strategic research update and not a formal financial report (like 10-K or IR) or a specific transaction announcement, it fits best under the general 'Regulatory Filings' category (RNS) as a corporate news release, although it shares characteristics with an Investor Presentation (IP) in content, the format is a standard press release announcing news, not a formal presentation deck. Given the options, RNS is the most appropriate fallback for a general corporate news announcement not covered elsewhere.
2016-01-05 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Investor Presentation Classification · 95% confidence The document is a press release dated January 5, 2016, announcing that Nanobiotix has started a new research program in Immuno-Oncology using its lead product NBTXR3. It details ongoing clinical trials and the scientific rationale for combining NBTXR3 with immunotherapy. This type of announcement, focusing on research progress, clinical pipeline updates, and strategic direction, is characteristic of an Investor Presentation (IP) or a general corporate update. Since it is a formal announcement detailing strategic scientific developments and pipeline status, 'Investor Presentation' (IP) is the most fitting category, as these releases often serve as key updates for investors regarding future value drivers, even if not explicitly formatted as a slide deck. It is not a formal regulatory filing like 10-K, an earnings release (ER), or a simple dividend notice (DIV). Given the depth of scientific and clinical detail, it goes beyond a basic Regulatory Filing (RNS).
2016-01-05 French
Communicated under the obligation to provide permanent information / Other communications
Legal Proceedings Report Classification · 99% confidence The document is a press release dated January 4th, 2016, announcing that the FDA approved an Investigational New Drug (IND) application for NBTXR3 for a new clinical study in prostate cancer. It details the study design, the product mechanism, and includes standard sections like 'About NANOBIOTIX' and 'Contact'/'Disclaimer'. This type of announcement, focusing on regulatory milestones (IND approval) and clinical trial initiation, is characteristic of an Earnings Release (ER) if it were summarizing period results, but since it is a specific, non-periodic regulatory/clinical update, it fits best under the general 'Regulatory Filings' (RNS) category, as it is a formal announcement of a significant event that doesn't fit the other specific categories like 10-K, IR, or DIV. It is not a transcript (CT), a management change (MANG), or a formal financial report (IR/10-K). Given the nature of the announcement (FDA IND approval), it is a significant regulatory event announcement.
2016-01-04 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release dated January 4, 2016, announcing that the US FDA accepted the Investigational New Drug (IND) application for NBTXR3, allowing Nanobiotix to start a Phase I/II clinical trial for Prostate Cancer in the US. This type of announcement, detailing regulatory progress, clinical trial initiation, and scientific updates, is characteristic of an announcement intended for investors and the public regarding ongoing development activities, rather than a formal periodic financial report (like 10-K or IR) or a transcript. It is a specific corporate update related to product development and regulatory milestones. Since there is no specific category for 'Clinical Trial Initiation Announcement' or 'Regulatory Milestone Update', and it is not a general regulatory filing (RNS) or a presentation (IP), the closest fit among the provided options that covers significant corporate/development news, especially when related to financing/capital structure changes or major operational updates, is often sought. However, given the content is purely about regulatory clearance for a clinical trial, it is a significant corporate event announcement. It is not an Earnings Release (ER), Management Discussion (MDA), or a Financing Update (CAP). It is a specific announcement about a product development step. In the absence of a dedicated 'Clinical Trial Update' category, and given it is a formal press release detailing a major operational/regulatory step, it falls best under a general Regulatory Filing (RNS) or potentially a Legal/Regulatory update (LTR), but LTR is for proceedings/lawsuits. Since it is a formal announcement of a regulatory clearance (IND acceptance), RNS (Regulatory Filings) serves as the best general category for non-standard, specific regulatory news that isn't a core financial report.
2016-01-04 French
Information relative au nombre total de droits de vote et d'actions composant le capital
Share Issue/Capital Change Classification · 95% confidence The document explicitly states it is providing 'Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social' (Monthly information relating to the total number of voting rights and shares comprising the share capital), referencing Article 223-16 of the AMF General Regulation. This type of filing, which reports changes in the total number of shares and voting rights, is a mandatory periodic disclosure in France. While it is a regulatory filing, the specific nature points towards a notification related to capital structure or share ownership changes. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). It is closest to a notification regarding share capital changes. Among the provided codes, 'SHA' (Share Issue/Capital Change) is the most appropriate fit for a regular update on the total number of shares and voting rights, as this directly relates to the capital structure.
2015-12-07 French

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.